This whitepaper outlines the principles of TPD and PROTACs, introduces the D2B concept, and explores how a D2B approach can streamline the DMTA cycle in PROTAC discovery. We explore recent literature and real-world examples to illustrate gains in speed, efficiency, and sustainability, and highlight practical considerations for scientists interested in adopting D2B in their own programs.
Sponsored by
Concept Life Sciences
Concept Life Sciences is a leading contract research organization (CRO) serving the global life sciences industry. For over 25 years, the company, and its heritage companies, have provided consultative and collaborative drug discovery and development services. Our approach, supported by passionate scientists and world-leading capabilities, enables clients to overcome complex scientific challenges across a broad range of therapeutic areas and modalities.